- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
JTO2021: Probability of recurrence of lung adenocarcinoma in situ and microinvasive adenocarcinoma is 0 after 10 years
Probability of recurrence of lung adenocarcinoma in situ and microinvasive adenocarcinoma. It is the first study to evaluate the 10-year recurrence rate of lung micro-invasive adenocarcinoma.
Like lung adenocarcinoma in situ, there were no cases of recurrence during follow-up. The study was published in the official JTO of IASLC, indicating that MIA has the same good prognosis as AIS and has been unanimously agreed by major international lung cancer researchers.
As mentioned in our previous article, it is not enough to count the non-recurrence rate of early lung cancer in 5 years after surgery. It is necessary to count the possibility of recurrence of lung carcinoma in situ and lung microinvasive adenocarcinoma after 10 years. Then now the article of JTO is here.
The 10-year recurrence rate of lung micro-invasive adenocarcinoma is 0: from the online study of JTO 2021.4.26. The author is Professor Masaya Yotsukura of Thoracic Surgery, National Cancer Center, Tokyo, Japan
Original: Long-term prognosis of patients with resected adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung
According to statistics from a number of previous studies, micro-invasive adenocarcinoma of the lung is the same as adenocarcinoma in situ, and the recurrence rate is 0 at 5 years after surgery. This study aims to count the possibility of recurrence of micro-invasive adenocarcinoma within 10 years after surgery.
The study reviewed patients who underwent lung cancer resections at the center from 1998 to 2010. There were 207 cases of lung carcinoma in situ and 317 cases of lung microinvasive adenocarcinoma. In the subsequent 10-year follow-up, neither recurrence was found.
Carcinoma in situ: adherent growth (a, b)
Micro-invasive adenocarcinoma: no more than 5mm infiltration range (c, d)
Probability of recurrence in 10 years: There is no recurrence in AIS and MIA. In addition, during the 10-year follow-up, 5.6% of patients in the AIS group developed recurrent lung primary adenocarcinoma, and 7.7% of the MIA group developed recurrent adenocarcinoma. New onsets are considered to be multiple primary rather than recurring.
The author believes that despite the possibility of recurring adenocarcinoma after surgery, the postoperative prognosis of lung micro-invasive adenocarcinoma is still very good, and AIS and MIA should be treated together and separately from other adenocarcinomas. For example, the choice of follow-up and surgery, or the method of surgery.
Of course, the author also mentioned that most of the surgical methods in this study are still lobectomy, and the subjectivity of pathologists also brings certain uncertainty to the results of the study.
Evaluation: This is the first study to evaluate the 10-year recurrence rate of lung micro-invasive adenocarcinoma. Like lung adenocarcinoma in situ, there were no cases of recurrence during follow-up. The study was published in the official JTO of IASLC, indicating that MIA has the same good prognosis as AIS and has been unanimously agreed by major international lung cancer researchers.
In addition, basically no recurrence for 10 years = no recurrence for life. This study provides strong evidence that the resection of lung micro-invasive adenocarcinoma is basically equivalent to a complete cure.
(source:internet, reference only)